Blisovi Fe 1/20 Kit
Product Images NDC 68180-865

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Blisovi Fe 1/20 (NDC 68180-865). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

80ca76da 51ef 499f 988a 4ded69035439 01

80ca76da 51ef 499f 988a 4ded69035439 01
Norethindrone Acetate is a chemical compound with a molecular formula of C2OH2O5 and a molecular weight of 340.46. It is impossible to provide additional information with only this text.*
FDA Label Image

80ca76da 51ef 499f 988a 4ded69035439 02

80ca76da 51ef 499f 988a 4ded69035439 02
Ethinyl estradiol is a compound with a molecular formula of C20H240 and a molecular weight of 296.40.*
FDA Label Image

80ca76da 51ef 499f 988a 4ded69035439 03

80ca76da 51ef 499f 988a 4ded69035439 03
This is a table showing the mortality rates per 100,000 woman years by age, smoking status, and oral contraceptive use for circulatory diseases. The table is divided into two sections: ever-users (non-smokers) and controls (non-smokers), and ever-users (smokers) and controls (smokers). The age groups are 15-24, 25-34, and 35-44. The source of the table is P.M. Layde and V. Beral, Reference 18.*
FDA Label Image

80ca76da 51ef 499f 988a 4ded69035439 04

80ca76da 51ef 499f 988a 4ded69035439 04
This text appears to be a collection of study names and results related to the use of combined oral contraceptives (COC). The studies include NICHD Women's Care Study, French E3N cohort study, shanghai Women's Health Study, The Nurses' Health Study II, and Oxford Family Planning Study among others. The results include effect estimations such as odds ratios (OR), relative risks (RR), and hazard ratios (HR) for the use of COC compared to never use in different population groups. However, there is no sufficient information on what health outcomes or conditions these studies were investigating, so it is difficult to provide any further interpretation.*
FDA Label Image

80ca76da 51ef 499f 988a 4ded69035439 05

80ca76da 51ef 499f 988a 4ded69035439 05
This is a guide for individuals starting their menstrual cycle, with instructions on how to label the days of the week based on the start date of their period. There is also a mention of a monthly self-breast exam, but no further information is provided.*
FDA Label Image

80ca76da 51ef 499f 988a 4ded69035439 06

80ca76da 51ef 499f 988a 4ded69035439 06
This is a calendar indicating the days of the week starting from Sunday. It is intended for tracking a menstrual cycle, and requires the user to place a label strip with the day of the week corresponding to the first day of their period. The text also mentions a self breast exam to be performed monthly, but no further information is provided.*
FDA Label Image

80ca76da 51ef 499f 988a 4ded69035439 07

80ca76da 51ef 499f 988a 4ded69035439 07
This appears to be a product label for a medication called Blisovi, containing norethindrone acetate and etfinyl esradiol tablets with ferrous fumarate tablets. It includes instructions for storage and the manufacturer's information. The other text seems to be scans of various non-English characters and an unrelated schedule for a monthly self-breast exam.*
FDA Label Image

80ca76da 51ef 499f 988a 4ded69035439 08

80ca76da 51ef 499f 988a 4ded69035439 08
Lupin Women's CareĀ® Blisovi~Fe 1/20 is an oral contraceptive intended to prevent pregnancy that contains norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets. The package is not child-resistant and each yellow tablet contains 1mg of norethindrone acetate and 0.02mg of ethinyl estradiol. The ferrous fumarate tablets are not USP for dissolution. The product does not protect against HIV infection or other sexually transmitted diseases. This information is intended for the patient to be provided by a physician. The package was manufactured on June 28th, 2010 in India. The website www.birthcontrolhealth.com may have additional information.*
FDA Label Image

80ca76da 51ef 499f 988a 4ded69035439 09

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.